|
⚠️ Professional Use Only This content is intended exclusively for licensed medical professionals. It does not constitute clinical advice. Always follow applicable regulations and guidelines in your jurisdiction. |
|
✍️ Written by: Celmade Editorial Team | AI-Assisted Content 🔬 Medically Reviewed by: Stella Williams, Medical Aesthetic Injector 📅 Published: May 5th, 2026 | Last Reviewed: May 5th, 2026 🔗 View Reviewer Full Profile → celmade.co/pages/team-stella-williams |
|
📌 Editorial Note: This article was drafted with AI assistance and reviewed, fact-checked, and approved by Stella Williams, a qualified Medical Aesthetic Injector. All clinical claims are supported by cited references. |
Injectable lipolytics — deoxycholic acid (DCA) and phosphatidylcholine/DCA combinations — are among the most technically demanding of all aesthetic injectables to administer safely. The reason is straightforward: DCA is cytolytic by design. It destroys cells. In the correct tissue plane, targeting subcutaneous adipocytes, this is precisely the therapeutic mechanism. In the wrong plane, at the wrong depth, or with incorrect product placement, it destroys non-target cells — dermis, muscle, nerve — with consequences that range from prolonged discomfort to visible, permanent injury.
The complication profile of lipolytic injectables is well-characterised from the DCA Phase 3 clinical trial programme and from two decades of real-world clinical experience in Korea and internationally. Most complications are preventable with correct patient selection, thorough pre-treatment marking, precise injection technique, and adequate patient counselling. The complications that do occur are in the majority of cases manageable — provided the practitioner recognises them promptly and responds appropriately.
This guide covers the complete lipolytic complications framework: the distinction between expected responses and genuine complications, the full spectrum of adverse events with their prevention and management, and the documentation requirements that protect patients and practitioners. For the complete clinical background, see the Complete Lipolytic Injectables Guide. For the submental protocol details that prevent most complications, see the Submental Fat Reduction Protocol guide.
The First Essential Distinction: Expected Response vs Genuine Complication
The most common 'complication' in lipolytic practice is a patient who was not adequately counselled about the expected post-treatment response presenting in alarm at the normal appearance of their treated area at 48–72 hours. This is not a complication — it is a counselling failure. Understanding and communicating the expected response so thoroughly that a patient can distinguish it from a genuine complication is the most important safety measure in lipolytic practice:
|
Feature |
Expected Post-Treatment Response |
Possible Genuine Complication |
|
Swelling |
Significant swelling peaking at 48–72 hours. Entire treatment zone swollen and puffy. Resolves progressively over 2–4 weeks. |
Swelling that continues to worsen beyond week 2 without any sign of resolution, OR asymmetric swelling significantly different between two treated sides, OR swelling with fever, purulent discharge, or extreme tenderness. |
|
Erythema (redness) |
Diffuse erythema across the treatment zone. Present at treatment, peaks at 24–48 hours, fades over 1–2 weeks. |
Erythema with distinct demarcated borders, progressive spreading beyond the treatment zone, streaking (tracking), or associated fever and systemic symptoms. |
|
Induration (firmness) |
The treated area will feel firm, hard, and indurated during the clearance phase — typically 1–6 weeks post-treatment. This is the macrophage-mediated inflammatory response to cellular debris. |
Discrete, firm, well-defined nodule that persists beyond 12 weeks, is not resolving, and was not present in the acute phase. |
|
Pain and tenderness |
Burning and stinging during the injection (DCA mechanism). Tenderness in the treated area for 1–2 weeks post-treatment. Moderate discomfort at peak swelling. |
Severe, worsening pain beyond week 2. Pain with significant fever. Pain at rest that prevents normal activity at week 3+. |
|
Bruising |
Bruising at injection sites, particularly around the submental vessels. Resolves within 1–2 weeks. |
Bruising that is expanding, worsening after day 3, or associated with a firm haematoma requiring drainage. |
|
Asymmetry |
Mild asymmetry in swelling between two sides is common and normal during the acute phase. Resolves as swelling subsides. |
Persistent asymmetry in fat reduction after full assessment at week 6–8 post-session. |
|
Numbness |
Mild, temporary numbness in the submental or treated zone. Resolves within weeks as the inflammatory response subsides. |
Motor weakness — difficulty moving the lower lip or chin (marginal mandibular nerve involvement). Requires prompt assessment and documentation. |
|
The counselling standard: Every patient treated with lipolytics must be able to answer 'yes' to all of the following questions at the end of their pre-treatment consultation: 'Do you understand that significant swelling is expected, peaking at 48–72 hours?' / 'Do you understand that the treated area will look worse before it looks better?' / 'Do you know what a genuine complication looks like — and what to do if you think you have one?' / 'Do you have a contact method to reach me if you are concerned?' If the answer to any of these is no, the counselling is incomplete. |
The Prevention Framework: How Most Complications Are Avoided
The overwhelming majority of lipolytic complications are preventable. The prevention framework has four pillars:
Pillar 1: Correct Patient Selection
• Confirm the concern is fat — not skin laxity, not muscle, not bony structure
• BMI at or near healthy range — avoid significantly overweight patients
• No active contraindications: infection, pregnancy, anticoagulants, dysphagia, thyroid pathology
• Realistic expectations confirmed before booking
• No active lymphadenopathy in the treatment zone
Pillar 2: Precise Anatomical Marking
• Mark in sitting position — not supine
• All four safe zone boundaries marked before injection begins
• 1cm grid within the marked zone — no injection outside marked boundaries
• Landmarks palpated and confirmed before marking: mandibular border, hyoid, oral commissure lines
Pillar 3: Correct Injection Technique
• Perpendicular needle angle — into subcutaneous fat, not through it
• Depth confirmed by tissue feel — soft/yielding = fat; firm resistance = muscle (withdraw)
• Aspiration before every injection — blood in syringe = abort and relocate
• 0.2ml per point — no larger boluses; excess volume increases diffusion beyond the target zone
• Slow, steady injection — rapid delivery increases pressure and product spread beyond target
Pillar 4: Thorough Post-Treatment Counselling
• Written post-treatment instructions — every patient, every session
• Clear description of expected timeline for all expected responses
• Explicit criteria for when to contact the clinic
• Direct contact number for the treating practitioner in the first 72 hours
• Scheduled review appointment at week 6–8 — not open-ended 'let us know how you get on'
The Lipolytic Complication Spectrum: Full Reference
|
Complication |
Severity |
Cause |
Prevention |
Recognition |
Management |
|
Prolonged oedema (> 4 weeks) |
Minor to moderate |
Slower-than-average inflammatory clearance. More common in older patients and larger treatment volumes. |
Appropriate volume per session. Compression garments. Patient selection. |
Swelling not resolving by week 4 at expected rate. |
Reassure and monitor. Oral anti-inflammatories (NSAIDs if not contraindicated). Gentle lymphatic massage from week 3. Review at week 8. Consider systemic steroids for severe prolonged response. |
|
Nodule formation |
Moderate |
Loculated inflammatory exudate or fat necrosis at individual injection points. More common with higher DCA concentrations or excessive volumes per point. |
Standard 0.2ml per point. Consistent concentration. Avoid deep dermis injection. |
Firm, palpable, distinct nodule(s) appearing at week 3–6 as acute swelling resolves. |
Most resolve spontaneously by 12 weeks with gentle massage and patience. Persistent nodules > 12 weeks: consider intralesional corticosteroid injection (triamcinolone 10–20mg/ml). Refer if not resolving. |
|
Skin surface changes (haematoma track, discolouration) |
Minor to moderate |
Superficial injection into the deep dermis or dermis-fat junction. DCA in the dermis causes dermal cell destruction. |
Correct injection depth — subcutaneous, not dermal. Depth confirmed by resistance feel. |
Discolouration, altered skin texture, or surface irregularity at injection site. May appear as darkened lines or irregular surface contour. |
Most mild surface changes resolve over weeks to months. Significant dermal injury may leave lasting surface texture change. Refer to dermatology if not resolving at 3 months. |
|
Skin ulceration / necrosis |
Serious |
DCA injected into or very close to the dermis in sufficient concentration to cause full-thickness skin damage. The most serious skin-related lipolytic complication. |
Strict subcutaneous depth. Never inject above the dermis-fat junction. Do not overfill individual points. |
Skin breakdown, ulceration, or blistering at injection site — typically appearing at days 3–7. |
Immediate wound care — appropriate dressings, antimicrobial cover if secondary infection develops. Refer to dermatology or plastic surgery. Document extensively. Inform the patient fully and document the information given. |
|
Marginal mandibular nerve injury (submental zone) |
Serious |
DCA reaches the marginal mandibular nerve through incorrect superior placement or product diffusion beyond the safe zone superior limit. |
Strict 1–1.5cm inferior margin from mandibular border. Never inject above the superior marking line. |
Visible lower lip or chin asymmetry. Asymmetric smile — one corner of mouth does not depress on animation. Patient reports 'my smile looks different'. May emerge hours after the session. |
Most cases are temporary neurapraxia — nerve inflammation from DCA proximity rather than direct injection. Reassure. Avoid further injections near the affected zone. Monitor to resolution (typically 2–6 weeks). If severe or not resolving by 6 weeks: refer maxillofacial surgery or neurology. |
|
Dysphagia (difficulty swallowing) |
Serious — requires urgent assessment |
DCA effect extending to the suprahyoid or infrahyoid strap muscles or to the laryngeal region from inferior safe zone violation. |
Strict inferior boundary — stay above the thyroid level. Never inject below the hyoid. |
Patient reports difficulty swallowing, a sensation of throat tightening, or change in voice quality after submental treatment. May occur hours post-procedure. |
Do not dismiss. Assess severity immediately. If mild: monitor closely, soft diet, and close telephone contact for 24 hours. If significant: refer to ENT urgently. If severe or associated with respiratory change: treat as emergency — 999. |
|
Infection / abscess |
Moderate to serious |
Introduction of pathogenic organisms into the injection site. Most commonly from inadequate skin preparation or injecting through actively inflamed skin. |
Thorough skin cleansing pre-injection. Do not inject through acne, active infection, or abraded skin. Single-dose vials only — no multi-dose vial cross-patient contamination. |
Localised erythema that is expanding rather than contracting beyond week 2. Purulent discharge. Fever. Extreme tenderness. Systemic signs of infection. |
Antibiotics appropriate to the likely causative organism (staphylococcal cover for skin-source infection). Oral antibiotics for mild infection. IV antibiotics + hospital referral for severe infection or abscess. Incision and drainage if abscess has formed. Document and report. |
|
Intravascular injection |
Serious to critical (depending on volume) |
DCA accidentally injected into a subcutaneous or named vessel. Very rare with aspiration. High-volume intravascular DCA injection could cause systemic cardiovascular effects. |
Aspirate before every injection. Never inject against resistance. If blood on aspiration: withdraw, compress 30 seconds, relocate 0.5cm. |
Pain significantly disproportionate to the normal DCA injection pain. Patient pallor, dizziness, or collapse immediately post-injection. Visible haematoma forming rapidly. |
If suspected: stop all injections. Keep patient supine. Assess vital signs. Call 999 if patient unwell. Apply compression if haematoma forming. Document and report as serious adverse event. |
|
Asymmetric fat reduction |
Minor — aesthetic concern |
Unequal product distribution between two sides. Inconsistent technique. Missing injection points on one side. |
Systematic grid technique. Count and confirm equal points per side. Symmetrical volume per side. |
Visible asymmetry in fat reduction at week 6–8 assessment — not at 2 weeks when swelling asymmetry is normal. |
One or two additional targeted sessions on the under-treated side at 6–8 week minimum interval. Photograph and document. |
|
Alopecia (hair loss) at treatment site |
Minor |
DCA effect on scalp hair follicles if product is placed near or reaches follicular structures. More relevant for scalp or cervical zone applications. |
Avoid injection near the hairline. Keep superior boundary below the hairline. |
Patchy hair loss at the injection site developing 2–4 weeks post-treatment. |
Generally temporary — most hair loss from DCA-related follicular inflammatory damage resolves as the follicles recover. Reassure. PDRN scalp treatment may support follicle recovery. |
Marginal Mandibular Nerve Injury: Detailed Management Protocol
Because marginal mandibular nerve injury is the most visible and most distressing of the serious lipolytic complications, it warrants a detailed management protocol:
Immediate Assessment (at the session or within 24 hours)
1. Ask about facial symmetry: At every post-treatment assessment, ask: 'Has your smile felt symmetrical? Can you pull down your lower lip equally on both sides?'
2. Observe for asymmetry: Ask the patient to smile, to pull their lower lip downward, and to push their chin forward. The marginal mandibular nerve controls the depressor labii inferioris and depressor anguli oris — muscles that pull the lower lip and corner of the mouth downward on animation.
3. Document findings: Record the degree of asymmetry, which specific movements are affected, and the timing of onset. Photograph the asymmetry on animation.
Grading and Response
|
Severity |
Clinical Finding |
Management |
|
Mild |
Subtle asymmetry visible on strong animation. Patient may not have noticed without specific examination. |
Reassure — this will likely resolve within 2–6 weeks. Monitor at 2-weekly intervals. No further injections in the zone. |
|
Moderate |
Clear asymmetry on normal animation. Visible in photographs and in normal conversation/expression. |
Full documentation. Thorough patient explanation. Oral corticosteroids for anti-inflammatory support if within 72 hours of onset (discuss with prescriber). Monitor at 2-weekly intervals. No further injections. Physiotherapy referral if not improving at 4 weeks. |
|
Severe |
Marked resting asymmetry. Significant functional impact on expression, eating, or speaking. |
Full documentation. Immediate referral to maxillofacial surgery or neurology for assessment. Patient support — this is extremely distressing. Document all conversations. Inform your medical indemnity insurer. |
What to Tell the Patient
|
Suggested explanation for marginal mandibular nerve neurapraxia: "The treatment has caused some temporary inflammation around a small nerve in your jaw area — the nerve that controls the movement of your lower lip on one side. This has made your smile appear slightly asymmetric. This type of nerve reaction is a known potential complication of this treatment, and I want to be completely transparent with you about what has happened. In the vast majority of cases like this, the nerve recovers completely as the inflammation subsides over the coming weeks — typically within 2 to 6 weeks. I will monitor you closely at regular intervals. I want you to contact me immediately if the asymmetry worsens or if you develop any difficulty swallowing or breathing, but I am expecting this to resolve. I have documented this fully and I am here to support you through it." |
Nodule Management: A Practical Protocol
Nodules are one of the most common concerns patients raise between sessions — particularly in the 3–8 week post-treatment window when acute swelling is resolving and the firmness of localised inflammatory collections becomes more apparent:
Distinguishing Normal Induration from Nodules
The entire treatment zone is firm and indurated for 2–4 weeks post-treatment as a normal part of the inflammatory clearance response. What distinguishes a nodule from normal post-treatment induration is:
• Location: Normal induration is diffuse across the treatment zone. A nodule is a discrete, focal area of firmness — clearly distinguishable from the surrounding tissue.
• Timing: Normal induration is present from day 1 and progressively softens. A nodule may become more apparent at weeks 3–6 as the surrounding induration resolves, leaving a discrete firm collection that is not softening.
• Size: Nodules are typically pea-sized (5–10mm). Larger collections may represent fat necrosis or loculated fluid and require review.
Management by Timeline
|
Timepoint |
Finding |
Action |
|
Weeks 3–8 |
Discrete firm nodule identified. Not resolving with surrounding swelling. |
Reassure. Gentle massage 2× daily. No further treatment — most resolve spontaneously. |
|
Weeks 8–12 |
Nodule persisting. Not softening despite massage. |
Continue massage. Consider whether the product was correctly placed. Review technique for subsequent sessions. |
|
Weeks 12+ |
Nodule still present. Not resolving. |
Intralesional corticosteroid injection: triamcinolone acetonide 10mg/ml, 0.1–0.2ml injected directly into the nodule. Repeat at 4-week intervals if needed (maximum 3 injections). Refer to dermatology if not resolving after 3 corticosteroid injections. |
|
Any time |
Nodule becoming painful, increasing in size, or associated with overlying skin changes (redness, warmth, fluctuance). |
Assess for infection — consider antibiotics. If fluctuant, may require aspiration. Refer if systemic signs present. |
Documentation Standards for Lipolytic Practice
Lipolytic treatments carry a higher adverse event rate and a higher clinical consequence for adverse events than most other aesthetic treatments. Documentation standards must be correspondingly rigorous:
Before Each Session
• Signed consent: Specific to the product and zone being treated. References expected post-treatment response and all specific risks. For off-label body applications, explicitly states off-label nature.
• Standardised photographs: All positions — frontal, lateral, chin-extended (submental). Every session, before treatment.
• Contraindication review: Medications, pregnancy, relevant medical history — reviewed at every session, not just the first.
• Product record: Product name, manufacturer, batch number, concentration, total volume used, and zone treated — every session.
During the Session
• Aspiration records: If aspiration-positive (blood) occurs, document which point, what was done, and where the subsequent injection was placed.
• Injection point count: Total injection points per side/zone documented.
• Any intra-session events: Patient reports of unusual pain, dizziness, or symptoms outside the expected DCA response — document immediately.
After the Session and at Review
• Post-treatment instructions given: Record that written post-treatment instructions were provided.
• Review appointment: Scheduled and documented — not left to patient initiative.
• Review findings: Clinical assessment at week 6–8: residual fat volume (pinch test), symmetry, skin quality, any complications. Compare to baseline photographs.
• Any adverse events: Full documentation of onset, severity, management, patient communication, and resolution or ongoing status.
|
Adverse event reporting: Serious adverse events from CE-marked medical devices — including severe nerve injury, skin necrosis, severe infection, and anaphylaxis — should be reported to the MHRA through the Yellow Card scheme. This is a professional obligation, not optional. Reporting also serves to build the UK safety dataset for these products and supports informed regulatory oversight of the injectable lipolytic category. |
When to Refer: Escalation Criteria
Not all complications can or should be managed in the aesthetic clinic. The following presentations require referral:
|
Clinical Finding |
Urgency |
Refer To |
|
Difficulty swallowing or voice change after submental treatment |
Urgent — same day |
ENT. Emergency services if respiratory compromise develops. |
|
Suspected intravascular injection with patient collapse or haemodynamic change |
Emergency — 999 |
Emergency services |
|
Severe infection / suspected abscess with systemic signs (fever > 38°C, rigors, rapidly spreading erythema) |
Urgent — same day |
A&E or acute medical assessment |
|
Skin necrosis — skin breakdown, ulceration, or full-thickness injury |
Urgent — within 24 hours |
Dermatology or plastic surgery |
|
Marginal mandibular nerve injury not improving at 6 weeks |
Non-urgent — arrange within 2 weeks |
Maxillofacial surgery or neurology |
|
Nodule not resolving after 3 intralesional corticosteroid injections |
Non-urgent — arrange within 1 month |
Dermatology |
|
Patient psychological distress disproportionate to the clinical finding |
Non-urgent but important |
Patient's GP — for psychological support referral. Practitioners should not attempt to manage significant psychological adverse reactions without medical support. |
Key Takeaways
• The most common 'complication' is inadequate pre-treatment counselling — a patient who presents alarmed at normal 48-hour swelling has experienced a counselling failure, not a clinical complication. The prevention is thorough, specific, written pre-treatment information.
• The four prevention pillars: correct patient selection, precise anatomical marking, correct injection technique, and thorough post-treatment counselling — virtually all complications trace back to a failure in one or more of these.
• Aspiration before every injection is non-negotiable — it does not eliminate vascular injection risk but it meaningfully reduces it. There is no clinical reason to skip aspiration.
• Marginal mandibular nerve injury is the most distressing serious complication — it is almost always a temporary neurapraxia that resolves within 2–6 weeks when the safe zone has been correctly marked. It becomes permanent only when the nerve itself is directly damaged rather than inflamed by adjacent product.
• Nodules are common, manageable, and usually self-resolving — reassure patients. Most resolve by week 12. Persistent nodules respond to intralesional corticosteroid.
• Document everything at every session — batch numbers, volumes, zones, post-treatment instructions, review findings, and any adverse events. In lipolytic practice, clinical documentation is a patient safety measure and a professional protection.
• Know the escalation threshold and never wait too long — dysphagia, respiratory change, systemic infection signs, and expanding skin injury are all urgent referral criteria.
For related guides: Complete Lipolytic Injectables Guide, Submental Fat Reduction: Protocol and Patient Selection, DCA vs PC/DCA: Choosing the Right Agent. Browse lipolytic products at Celmade.
Frequently Asked Questions
How common are serious complications from lipolytic injections?
Serious complications are uncommon when the treatment is performed correctly by an appropriately trained practitioner with appropriate product in appropriate patients. The DCA Phase 3 trials reported marginal mandibular nerve injury in approximately 4% of patients, with the vast majority resolving fully. Skin necrosis is rare — reported primarily in cases of dermal-level injection or excessive volumes per point. The most common adverse events in these trials were the expected post-treatment responses (swelling, erythema, pain, numbness) rather than true complications. For full adverse event data, see the Kybella prescribing information and clinical trial data (Dayan et al. 2016 Phase 3 trials).
What should I do if a patient calls me in alarm about their swelling at 48 hours?
If you have counselled the patient correctly, they should be calling to report that the expected swelling is present — not in alarm about an unexpected event. When a patient calls concerned: (1) Listen fully to their description. (2) Confirm the specific features of what they are experiencing — is it within the bounds of the expected response or does it have features of a complication (rapidly expanding, fever, discharge, breathing change)? (3) If it sounds like the expected response: reassure clearly, confirm the specific expectations you discussed at consultation, and advise ice and anti-inflammatories if appropriate. (4) If any features suggest a genuine complication: bring the patient in immediately for assessment. Do not reassure without assessment when there is any doubt.
Can nodules after lipolytic treatment be dissolved?
Lipolytic nodules are composed of inflammatory tissue and localised fat necrosis products — not hyaluronic acid — so hyaluronidase has no role in their management. Most resolve spontaneously with gentle massage and patience by week 12. For persistent nodules, intralesional corticosteroid injection (triamcinolone 10mg/ml) is the treatment of choice. Some practitioners have used ultrasound-guided aspiration for larger collections. Surgical removal is rarely needed but available for nodules that are very large, very persistent, or cosmetically significant.
Should I have hyaluronidase available for lipolytic emergencies?
Hyaluronidase is not relevant to DCA or PC/DCA complications — it dissolves hyaluronic acid and has no effect on DCA-induced tissue injury. The emergency kit for lipolytic treatment should instead include: antihistamine (for allergic reaction), adrenaline/epinephrine auto-injector (for anaphylaxis), oral corticosteroids (for severe inflammatory response), appropriate wound care dressings (for skin necrosis), and direct emergency contact numbers (999, local A&E). Practitioners who also administer HA products in the same clinic should of course have hyaluronidase available for HA-related complications — but it is not a lipolytic emergency tool.
How long after treatment can complications appear?
The timeline varies by complication type: marginal mandibular nerve injury typically appears within hours of the session as the local anaesthetic wears off; skin surface changes appear at 3–7 days; nodule formation becomes apparent at weeks 3–8 as surrounding swelling resolves; infection can appear at any point from day 1 to 3 weeks post-treatment; asymmetric fat reduction is only assessable at the week 6–8 review. The review appointment at week 6–8 is the essential clinical safety net for identifying delayed complications — practitioners who do not schedule formal reviews miss the clinical window to assess outcomes objectively and identify delayed adverse events.
